NCT05168436已完成不适用
Preferences Of Patients And Oncologists For The Characteristics Of The Treatment For RCC In Spain And Portugal
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2019年8月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 105
- 试验地点
- 1
- 主要终点
- Utility: Renal cell carcinoma (RCC) participants' preferences
研究概览
简要总结
The purpose of this observational study is to determine patients' and professionals' preferences for the characteristics (attributes) of the treatment for Renal cell carcinoma (RCC) in Spain and Portugal.
详细描述
This study uses a literature review, qualitative (focus groups) and quantitative methods (discrete-choice experiment, DCE) to determine renal cell carcinoma (RCC) participants and oncologists' preferences. In this clinical trial, the study team will develop a survey consisting of comparisons of hypothetical treatment profiles (scenarios). Scenarios are presented to participants, and each participant chooses the most preferable.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Oncologists from Spain and Portugal will be identified by the promoter and invited to participate in the study in accordance with the inclusion criteria described below.
- •The oncologist is currently working in a Spanish or Portuguese public hospital.
- •The oncologist has at least 2 years of experience in the management of participants with Renal Cell Carcinoma (RCC).
- •The oncologist has agreed to participate in the study.
- •Participants with a diagnosis of RCC will be identified and recruited by the Principal Investigators of the study, taking into account the inclusion criteria described below.
- •The participant has been diagnosed with RCC for a minimum of 2 months before study inclusion.
- •The participant has received or is currently receiving pharmacological treatment for RCC;
- •The participant has provided the informed consent to participate in the study.
- •The participant must be able to read, understand and complete the survey instrument according to the judgment of the responsible physician.
排除标准
- •Not applicable
结局指标
主要结局
Utility: Renal cell carcinoma (RCC) participants' preferences
时间窗: At Baseline
Utility (preference score) derived for a treatment alternative choice (scenario)
Utility: Oncologists' preferences
时间窗: At Baseline
Utility (preference score) derived for a treatment alternative choice (scenario)
次要结局
- Distribution of socio-demographic characteristics of Renal cell carcinoma (RCC) participants: Age(At Baseline)
- Distribution of clinical characteristics of RCC participants: Time since RCC diagnosis(At Baseline)
- Distribution of socio-demographic characteristics of RCC participants: Working situation(At Baseline)
- Distribution of socio-demographic characteristics of RCC participants: Other costs derived from the visit to the hospital (parking, meals...)(At Baseline)
- Distribution of clinical characteristics of RCC participants: American Joint Committee on Cancer (AJCC) Staging(At Baseline)
- Distribution of clinical characteristics of RCC participants: Charlson index(At Baseline)
- Distribution of clinical characteristics of RCC participants: Karnofsky Performance Scale Index(At Baseline)
- Distribution of clinical characteristics of RCC participants: Identification of previous pharmacological treatments received by the participant for the treatment of RCC(At Baseline)
- Distribution of socio-demographic characteristics of oncologists: Gender(At Baseline)
- Distribution of socio-demographic characteristics of oncologists: Years of experience in oncology(At Baseline)
- Distribution of socio-demographic characteristics of RCC participants: Place of residence(At Baseline)
- Distribution of socio-demographic characteristics of RCC participants: Gender(At Baseline)
- Distribution of socio-demographic characteristics of RCC participants: Economic status (income)(At Baseline)
- Distribution of socio-demographic characteristics of RCC participants: Education level(At Baseline)
- Distribution of clinical characteristics of RCC participants: Current drug treatment (if applicable)(At Baseline)
- Distribution of socio-demographic characteristics of oncologists: Other types of cancer treated(At Baseline)
- Distribution of socio-demographic characteristics of oncologists: Level/ classification of hospital where employed(At Baseline)
- Distribution of socio-demographic characteristics of RCC participants: Transport to the hospital: means, duration and cost(At Baseline)
- Distribution of clinical characteristics of RCC participants: Description of previous pharmacological treatments received by the participant for the treatment of RCC(At Baseline)
- Distribution of socio-demographic characteristics of oncologists: Age(At Baseline)
- Distribution of socio-demographic characteristics of oncologists: Province where employed(At Baseline)
- Distribution of socio-demographic characteristics of oncologists: Years of experience in RCC(At Baseline)
- Distribution of socio-demographic characteristics of oncologists: Number of participants with RCC seen per year(At Baseline)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer TreatmentsNon-small Cell Lung Cancer (NSCLC)NCT06448793Bristol-Myers Squibb650
已完成
不适用
The PAtient Preference Analysis of Yearly Follow-up After PCI (PAPAYA)Coronary Artery DiseaseNCT02189070Thorax Centrum Twente2,566
已完成
不适用
Survey Based Discrete Choice Experiment Study in Prostate Cancer (DECIDER) StudyMetastatic Hormone-sensitive Prostate CancerProstate CancerNCT05381311Astellas Pharma Global Development, Inc.1,020
已完成
不适用
The Pain App Study: A Novel Shared Decision Making Tool for People With Chronic PainChronic PainNCT03425266Shared Decision Making Resources80
已完成
不适用
Survey of Health Preferences in Cancer Patients (QALY-Cancer)Breast CancerColorectal CancerNCT03560817Centre de recherche du Centre hospitalier universitaire de Sherbrooke198